<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37390772</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice.</ArticleTitle><Pagination><StartPage>104682</StartPage><MedlinePgn>104682</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">104682</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2023.104682</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(23)00247-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">RNA viruses account for many human diseases and pandemic events but are often not targetable by traditional therapeutics modalities. Here, we demonstrate that adeno-associated virus (AAV) -delivered CRISPR-Cas13 directly targets and eliminates the positive-strand EV-A71 RNA virus in cells and infected mice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed a Cas13gRNAtor bioinformatics pipeline to design CRISPR guide RNAs (gRNAs) that cleave conserved viral sequences across the virus phylogeny and developed an AAV-CRISPR-Cas13 therapeutics using in vitro viral plaque assay and in vivo EV-A71 lethally-infected mouse model.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We show that treatment with a pool of AAV-CRISPR-Cas13-gRNAs designed using the bioinformatics pipeline effectively blocks viral replication and reduces viral titers in cells by &gt;99.99%. We further demonstrate that AAV-CRISPR-Cas13-gRNAs prophylactically and therapeutically inhibited viral replication in infected mouse tissues and prevented death in a lethally challenged EV-A71-infected mouse model.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our results show that the bioinformatics pipeline designs efficient CRISPR-Cas13 gRNAs for direct viral RNA targeting to reduce viral loads. Additionally, this new antiviral AAV-CRISPR-Cas13 modality represents an effective direct-acting prophylactic and therapeutic agent against lethal RNA viral infections.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Agency for Science, Technology and Research (A∗STAR) Assured Research Budget, A∗STAR Central Research Fund UIBR SC18/21-1089UI, A∗STAR Industrial Alignment Fund Pre-Positioning (IAF-PP) grant H17/01/a0/012, MOE Tier 2 2017 (MOE2017-T2-1-078; MOE-T2EP30221-0005), and NUHSRO/2020/050/RO5+5/NUHS-COVID/4.</AbstractText><CopyrightInformation>Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keng</LastName><ForeName>Choong Tat</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Genome Institute of Singapore, Agency for Science, Technology and Research, 60 Biopolis Street, Singapore 138672, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yogarajah</LastName><ForeName>Thinesshwary</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Infectious Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Regina Ching Hua</ForeName><Initials>RCH</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhammad</LastName><ForeName>Irfan Bin Hajis</ForeName><Initials>IBH</Initials><AffiliationInfo><Affiliation>Genome Institute of Singapore, Agency for Science, Technology and Research, 60 Biopolis Street, Singapore 138672, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chia</LastName><ForeName>Bing Shao</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Genome Institute of Singapore, Agency for Science, Technology and Research, 60 Biopolis Street, Singapore 138672, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasandani</LastName><ForeName>Suraj Rajan</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Genome Institute of Singapore, Agency for Science, Technology and Research, 60 Biopolis Street, Singapore 138672, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Daryl Shern</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Genome Institute of Singapore, Agency for Science, Technology and Research, 60 Biopolis Street, Singapore 138672, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Genome Institute of Singapore, Agency for Science, Technology and Research, 60 Biopolis Street, Singapore 138672, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Yi Hao</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>NUSMed Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, 14 Medical Drive, 117599, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Chee Keng</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>NUSMed Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, 14 Medical Drive, 117599, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Justin Jang Hann</ForeName><Initials>JJH</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A∗STAR), 61 Biopolis Drive, Proteos #06-05, 138673, Singapore; Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Infectious Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore; NUSMed Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, 14 Medical Drive, 117599, Singapore. Electronic address: miccjh@nus.edu.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Wei Leong</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Genome Institute of Singapore, Agency for Science, Technology and Research, 60 Biopolis Street, Singapore 138672, Singapore; Synthetic Biology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, 117596, Singapore. Electronic address: chewwl@gis.a-star.edu.sg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adeno-associated viral vectors</Keyword><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">CRISPR-Cas13d</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Prophylactic</Keyword><Keyword MajorTopicYN="N">Therapeutic</Keyword></KeywordList><CoiStatement>Declaration of interests CTK, RCHL, TY, JJHC, and WLC have filed patents and provisional applications based on this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>1</Day><Hour>11</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>30</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37390772</ArticleId><ArticleId IdType="pmc">PMC10363442</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104682</ArticleId><ArticleId IdType="pii">S2352-3964(23)00247-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Woolhouse M.E.J., Brierley L. Epidemiological characteristics of human-infective RNA viruses. Sci Data. 2018;5:1–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819479</ArticleId><ArticleId IdType="pubmed">29461515</ArticleId></ArticleIdList></Reference><Reference><Citation>Doud M.B., Lee J.M., Bloom J.D. How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Nat Commun. 2018;9(1):1–12. doi: 10.1038/s41467-018-03665-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03665-3</ArticleId><ArticleId IdType="pmc">PMC5895760</ArticleId><ArticleId IdType="pubmed">29643370</ArticleId></ArticleIdList></Reference><Reference><Citation>Belshaw R., Gardner A., Rambaut A., Pybus O.G. Pacing a small cage: mutation and RNA viruses. Trends Ecol Evol. 2008;23(4):188–193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125972</ArticleId><ArticleId IdType="pubmed">18295930</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., St Denis K., et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–2383.e9. doi: 10.1016/j.cell.2021.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC7953441</ArticleId><ArticleId IdType="pubmed">33743213</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Greaney A.J., Addetia A., et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371(6531):850–854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963219</ArticleId><ArticleId IdType="pubmed">33495308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi M.H., Wong S.C., Lewthwaite P., Cardosa M.J., Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097–1105. doi: 10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Zhang R., Wu W., Duan G. Innate immunity evasion by enteroviruses linked to epidemic hand-foot-mouth disease. Front Microbiol. 2018;9(OCT):2422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6186807</ArticleId><ArticleId IdType="pubmed">30349526</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.-M., Ho T.-S., Lin H.-C., Lei H.-Y., Wang J.-R., Liu C.-C. Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity. Eur J Clin Microbiol Infect Dis. 2012;31(6):1219–1224. doi: 10.1007/s10096-011-1432-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-011-1432-6</ArticleId><ArticleId IdType="pubmed">21983920</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J., Liu F., Qi H., et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013-2019: a population-based study. Lancet Reg Health West Pac. 2022;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8743221</ArticleId><ArticleId IdType="pubmed">35036978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi E.J., Shin Y.J., Kim J.H., Kim T.G., Chang S.Y. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6(1):4–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.W., Chu J.J.H. Protecting the most vulnerable from hand, foot, and mouth disease. Lancet Infect Dis. 2021;21(3):308–309.</Citation><ArticleIdList><ArticleId IdType="pubmed">33031751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.Y., Kung Y.A., Shih S.R. Antivirals and vaccines for enterovirus A71. J Biomed Sci. 2019;26(1):1–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6720414</ArticleId><ArticleId IdType="pubmed">31481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–828.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo F.M.S., Nyo M., Wong A.A., et al. Cytokine and chemokine profiling in patients with hand, foot and mouth disease in Singapore and Malaysia. Sci Rep. 2018;8(1):1–9. doi: 10.1038/s41598-018-22379-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-22379-6</ArticleId><ArticleId IdType="pmc">PMC5840398</ArticleId><ArticleId IdType="pubmed">29511232</ArticleId></ArticleIdList></Reference><Reference><Citation>Konermann S., Lotfy P., Brideau N.J., Oki J., Shokhirev M.N., Hsu P.D. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell. 2018;173(3):665–676.e14. doi: 10.1016/j.cell.2018.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.02.033</ArticleId><ArticleId IdType="pmc">PMC5910255</ArticleId><ArticleId IdType="pubmed">29551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W.X., Chong S., Zhang H., et al. Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. Mol Cell. 2018;70(2):327–339.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935466</ArticleId><ArticleId IdType="pubmed">29551514</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott T.R., Dhamdhere G., Liu Y., et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell. 2020;181(4):865–876.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189862</ArticleId><ArticleId IdType="pubmed">32353252</ArticleId></ArticleIdList></Reference><Reference><Citation>Koujah L., Shukla D., Naqvi A.R. CRISPR-Cas based targeting of host and viral genes as an antiviral strategy. Semin Cell Dev Biol. 2019;96:53–64. doi: 10.1016/j.semcdb.2019.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2019.04.004</ArticleId><ArticleId IdType="pmc">PMC6783345</ArticleId><ArticleId IdType="pubmed">30953741</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard E.L., Vanover D., Bawage S.S., et al. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents. Nat Biotechnol. 2021;39(6):717–726. doi: 10.1038/s41587-021-00822-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-00822-w</ArticleId><ArticleId IdType="pubmed">33536629</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Wang S., Dong X., et al. CRISPR-Cas13a cleavage of dengue virus NS3 gene efficiently inhibits viral replication. Mol Ther Nucleic Acids. 2020;19:1460–1469. doi: 10.1016/j.omtn.2020.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2020.01.028</ArticleId><ArticleId IdType="pmc">PMC7056623</ArticleId><ArticleId IdType="pubmed">32160714</ArticleId></ArticleIdList></Reference><Reference><Citation>Freije C.A., Myhrvold C., Boehm C.K., et al. Programmable inhibition and detection of RNA viruses using Cas13. Mol Cell. 2019;76(5):826–837.e11. doi: 10.1016/j.molcel.2019.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2019.09.013</ArticleId><ArticleId IdType="pmc">PMC7422627</ArticleId><ArticleId IdType="pubmed">31607545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf M.U., Salman H.M., Khalid M.F., et al. CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategy. Biomed Pharmacother. 2021;136</Citation><ArticleIdList><ArticleId IdType="pubmed">33454599</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant L.M., Christopher D.M., Giles A.R., et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev. 2013;24(2):55–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992977</ArticleId><ArticleId IdType="pubmed">23808604</ArticleId></ArticleIdList></Reference><Reference><Citation>Bainbridge J.W.B., Mehat M.S., Sundaram V., et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med. 2015;372(20):1887–1897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4497809</ArticleId><ArticleId IdType="pubmed">25938638</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell S., Bennett J., Wellman J.A., et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849–860. doi: 10.1016/S0140-6736(17)31868-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31868-8</ArticleId><ArticleId IdType="pmc">PMC5726391</ArticleId><ArticleId IdType="pubmed">28712537</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Samulski R.J. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21(4):255–272. doi: 10.1038/s41576-019-0205-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-019-0205-4</ArticleId><ArticleId IdType="pubmed">32042148</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan E.L., Tan T.M.C., Tak Kwong Chow V., Poh C.L. Inhibition of enterovirus 71 in virus-infected mice by RNA interference. Mol Ther. 2007;15(11):1931–1938.</Citation><ArticleIdList><ArticleId IdType="pubmed">17712333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels H.-H., Méndez-Mancilla A., Guo X., Legut M., Daniloski Z., Sanjana N.E. Massively parallel Cas13 screens reveal principles for guide RNA design. Nat Biotechnol. 2020;38(6):722–727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7294996</ArticleId><ArticleId IdType="pubmed">32518401</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon C.E. A mathematical theory of communication. Bell Syst Tech J. 1948;27(4):623–656.</Citation></Reference><Reference><Citation>Chew W.L., Tabebordbar M., Cheng J.K.W., et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods. 2016;13(10):868–874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374744</ArticleId><ArticleId IdType="pubmed">27595405</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A., Davis C.A., Schlesinger F., et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y., Smyth G.K., Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923–930.</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Yogarajah T., Lee R.C.H., et al. Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications. Sci Rep. 2020;10(1):8159. doi: 10.1038/s41598-020-65152-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-65152-4</ArticleId><ArticleId IdType="pmc">PMC7235037</ArticleId><ArticleId IdType="pubmed">32424333</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J.R.P.M., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16(6):368–381. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen I.-Y., Ichinohe T. Response of host inflammasomes to viral infection. Trends Microbiol. 2015;23(1):55–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">25456015</ArticleId></ArticleIdList></Reference><Reference><Citation>Awomoyi A.A. The human solute carrier family 11 member 1 protein (SLC11A1): linking infections, autoimmunity and cancer? FEMS Immunol Med Microbiol. 2007;49(3):324–329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890654</ArticleId><ArticleId IdType="pubmed">17378896</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Weng L., Zhang N., et al. Biochemical characterization of enterovirus 71 3D RNA polymerase. Biochim Biophys Acta. 2011;1809(3):211–219.</Citation><ArticleIdList><ArticleId IdType="pubmed">21220056</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Yu J., Qi X., Yan H. Monoclonal antibody against EV71 3D(pol) inhibits the polymerase activity of RdRp and virus replication. BMC Immunol. 2019;20(1):6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343263</ArticleId><ArticleId IdType="pubmed">30669993</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden L., Vives-Adrián L., Selisko B., et al. The RNA template channel of the RNA-dependent RNA polymerase as a target for development of antiviral therapy of multiple genera within a virus family. PLoS Pathog. 2015;11(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4370873</ArticleId><ArticleId IdType="pubmed">25799064</ArticleId></ArticleIdList></Reference><Reference><Citation>Abudayyeh O.O., Gootenberg J.S., Essletzbichler P., et al. RNA targeting with CRISPR-Cas13. Nature. 2017;550(7675):280–284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5706658</ArticleId><ArticleId IdType="pubmed">28976959</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Ennis J., Turner J.D., Chu J.J.H. Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge. Antiviral Res. 2016;134:207–215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113890</ArticleId><ArticleId IdType="pubmed">27623347</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim A.C.N., Luhur A., Tan T.M.C., Chow V.T.K., Poh C.L. RNA interference against enterovirus 71 infection. Virology. 2005;341(1):72–79.</Citation><ArticleIdList><ArticleId IdType="pubmed">16083932</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell J.E., Lim C.K.W., Krishnan R., et al. Targeted gene silencing in the nervous system with CRISPR-Cas13. Sci Adv. 2022;8(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769545</ArticleId><ArticleId IdType="pubmed">35044815</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin W.-X., Ang S.K., Chu J.J.H. Recent advances in therapeutic recruitment of mammalian RNAi and bacterial CRISPR-Cas DNA interference pathways as emerging antiviral strategies. Drug Discov Today. 2017;22(1):17–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">27575999</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoasii L., Hildyard J.C.W., Li H., et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science. 2018;362(6410):86–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6205228</ArticleId><ArticleId IdType="pubmed">30166439</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Ren S., Bai R., et al. No off-target mutations in functional genome regions of a CRISPR/Cas9-generated monkey model of muscular dystrophy. J Biol Chem. 2018;293(30):11654–11658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066302</ArticleId><ArticleId IdType="pubmed">29941452</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.-X., Zhai H., Shi Y., et al. Efficacy and long-term safety of CRISPR/Cas9 genome editing in the SOD1-linked mouse models of ALS. Commun Biol. 2021;4(1):396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7994668</ArticleId><ArticleId IdType="pubmed">33767386</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno A.M., Palmer N., Alemán F., et al. Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy. Nat Biomed Eng. 2019;3(10):806–816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783354</ArticleId><ArticleId IdType="pubmed">31332341</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>